The latest license-out!

On September 8, 2021, Biotech Biopharmaceutical Co.
, Ltd.
announced that it has signed a commercialization and licensing agreement for BAT1706 with Sandoz
.
BAT1706 is a biosimilar drug developed with reference to Avastin® (bevacizumab) and is an anti-vascular endothelial growth factor (VEGF) monoclonal antibody

According to the terms of the agreement, Biotech will be responsible for the product development, production and supply of BAT1706
.
After obtaining relevant regulatory approvals, Sandoz will be responsible for the commercialization of BAT1706 in the United States, Europe, Canada and most other international markets not covered by BAT1706 cooperation

BAT1706 is a bevacizumab developed by Biotech.
It works by binding to vascular endothelial growth factor (VEGF), blocking the binding of VEGF and its receptor, thereby reducing the formation of new blood vessels and inducing degradation of existing blood vessels , To achieve the effect of inhibiting tumor growth
.
In the United States and Europe, Avastin® has been approved for the treatment of multiple indications, including metastatic colorectal cancer, non-squamous non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical cancer, and ovarian cancer cancer, fallopian tube cancer, peritoneal cancer, breast cancer and so on

At present, BAT1706 has completed a large number of similarity studies including global phase III clinical trials, and has reported to China National Medical Products Administration (NMPA), European Medicines Agency (EMA), and U.
S.
Food and Drug Administration (FDA).
The application for marketing authorization was submitted and accepted
.

Sandoz is a global leader in the field of generic drugs and biosimilars.
Since Edouard Sandoz founded Sandoz in the 19th century in 1886, it has been known for its outstanding quality
.

Not long ago, on August 27, Biotech and Hikma jointly announced the signing of an exclusive commercialization and licensing agreement for BAT2206 (a biosimilar developed with reference to Starnox® Usnumab) in the US market.

.
According to the terms of the agreement, Biotech will be responsible for the development, production and supply of BAT2206

BAT2206 is a biosimilar drug developed with reference to Starnox® (Usnumab).
It is a fully human monoclonal antibody targeting the p40 subunit shared by IL-12 and IL-23
.
IL-12 and IL-23 are naturally produced cytokines that can participate in inflammation and immune response processes.

The cross-border license-out of China's pharmaceuticals is one of the manifestations of international recognition of its R&D strength, and it is also a way for local pharmaceutical companies to enter the international market, and internationalization is the only way for Chinese pharmaceutical companies to rise
.
As domestic pharmaceutical companies continue to increase their R&D capabilities, cross-border license-out transactions in pharmaceuticals are gradually becoming more routine